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Abstract
Background: Mutations in KRAS are frequent in human cancer, yet effective targeted therapeutics for these cancers
are still lacking. Attempts to drug the MEK kinases downstream of KRAS have had limited success in clinical trials.
Understanding the specific genomic vulnerabilities of KRAS-driven cancers may uncover novel patient-tailored
treatment options.
Methods: We first searched for synthetic lethal (SL) genetic interactions with mutant RAS in yeast with the ultimate
aim to identify novel cancer-specific targets for therapy. Our method used selective ploidy ablation, which enables
replication of cancer-specific gene expression changes in the yeast gene disruption library. Second, we used a
genome-wide CRISPR/Cas9-based genetic screen in KRAS mutant human colon cancer cells to understand the
mechanistic connection between the synthetic lethal interaction discovered in yeast and downstream RAS signaling
in human cells.
Results: We identify loss of the endoplasmic reticulum (ER) stress sensor IRE1 as synthetic lethal with activated RAS
mutants in yeast. In KRAS mutant colorectal cancer cell lines, genetic ablation of the human ortholog of IRE1, ERN1,
does not affect growth but sensitizes to MEK inhibition. However, an ERN1 kinase inhibitor failed to show synergy
with MEK inhibition, suggesting that a non-kinase function of ERN1 confers MEK inhibitor resistance. To investigate
how ERN1 modulates MEK inhibitor responses, we performed genetic screens in ERN1 knockout KRAS mutant colon
cancer cells to identify genes whose inactivation confers resistance to MEK inhibition. This genetic screen identified
multiple negative regulators of JUN N-terminal kinase (JNK) /JUN signaling. Consistently, compounds targeting JNK/
MAPK8 or TAK1/MAP3K7, which relay signals from ERN1 to JUN, display synergy with MEK inhibition.
Conclusions: We identify the ERN1-JNK-JUN pathway as a novel regulator of MEK inhibitor response in KRAS mutant
colon cancer. The notion that multiple signaling pathways can activate JUN may explain why KRAS mutant
tumor cells are traditionally seen as highly refractory to MEK inhibitor therapy. Our findings emphasize the
need for the development of new therapeutics targeting JUN activating kinases, TAK1 and JNK, to sensitize
KRAS mutant cancer cells to MEK inhibitors.
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Background
Mutation of specific codons in one of the three RAS
genes HRAS, KRAS, or NRAS converts these genes into
oncogenes. These mutations are found in a wide variety
of tumors, with very high incidences (> 50%) in pancreas
and colon cancers [1]. Despite decades of research, gen-
eration of selective inhibitors of mutant RAS has proven
to be difficult. Recently, allosteric inhibitors of KRAS
G12C have been developed [2, 3], but the clinical effect-
iveness of these compounds remains to be established.
RAS genes are highly conserved in evolution. The yeast
Saccharomyces cerevisiae has two RAS genes: RAS1 and
RAS2. These two genes are individually not required for
cell viability. However, the double deletion mutant is in-
viable, indicating that the genes share an essential function
[4]. A yeast ras1Δ ras2Δ deletion mutant can be rescued by
ectopic expression of a human RAS gene [5]. Vice versa,
mutating codon 19 into a valine converts yeast RAS into a
constitutively active protein and this mutant yeast RAS can
induce malignant transformation of mouse fibroblasts [6].
We searched for synthetic lethal (SL) genetic interac-
tions with mutant RAS in yeast to identify novel
cancer-specific targets for therapy. Our method uses se-
lective ploidy ablation (SPA) and allows us to mimic
cancer-specific gene expression changes in each of the
4800 nonessential deletion mutant strains in the yeast
gene disruption library [7]. Using this approach, we
found that inhibition of yeast unfolded protein response
(UPR) genes is synthetic lethal with mutant RAS.
The UPR in yeast is mediated by Ire1 and Hac1 [8]. Ire1
is an endonuclease that upon endoplasmic reticulum (ER)
stress splices HAC1 mRNA. Hac1 is a transcription factor
that executes the UPR by activating genes involved in ER
homeostasis. The UPR, and the mechanism of activation
by splicing of a specific mRNA, is conserved from yeast to
humans. Mammalian cells have an IRE1 ortholog named
ERN1. Likewise, HAC1 has a functional human homolog,
XBP1 [9]. In mammalian KRAS mutant colon cancer, we
find that inhibition of MEK kinases is synthetic lethal with
inhibition of the UPR. Our findings establish an unex-
pected link between MEK kinase signaling and the UPR
executor ERN1 in human cancer.
Methods
Yeast screen
Wild-type RAS alleles were cloned into pWJ1512 using the
A and B adaptamers [10]. Primers to obtain mutant RAS








The SPA protocol [7] was used to transfer plasmids
into the arrayed gene disruption library [11]. Briefly,
SPA is a yeast mating-based protocol that allows transfer
of a plasmid from a special donor strain into a recipient
strain followed by destabilization and counter-selection
of the donor yeast chromosomes. The method was
adapted for the RAS screen by adding 2% raffinose in
addition to 2% galactose as a carbon source for the last
two selection steps. In addition, selection steps for
RAS2(V19) cells were 1 day longer because overall
growth is slower in these strains.
Cell culture, transfection and lentiviral infection
HEK293 cells were cultured in DMEM. All other cell lines
were maintained in RPMI1640 medium containing 10%
FBS and 1% penicillin/streptomycin at 37 °C and 5% CO2.
All cell lines were purchased from the American Type
Culture Collection (ATCC), STR profiled (by Eurofins
Medigenomix Forensik GmbH, Ebersberg, Germany), and
routinely tested negative for mycoplasma.
Transfection of HEK293 cells with linear polyethyleni-
mine (PEI) 25K from Polysciences (cat# 23966-2) and sub-
sequent infection of target cells was done as described
previously [12]. For knockout of individual genes, the fol-
lowing single-guide (sg) RNAs were cloned in the lenti-
CRISPR version 2.1 (LC2.1) vector by Gibson cloning:
sgERN1-A, 5′-ACATCCCGAGACACGGTGGT-3′; sgERN1-
B, 5′-GATGGCAGCCTGTATACGCT-3′; sgDET1, 5′-AC
GTGCAGCAGTGTCGCATA-3′; sgCOP1, 5′-AAGCTCC
TTCTCCATCACAC-3′. Non-targeting (NT) sgRNA
5′-ACGGAGGCTAAGCGTCGCAA-3′ was used as a
control.
Cell proliferation assays and growth curves
For long-term cell proliferation assays, cells were seeded
in six-well plates at densities ranging from 1 to 2 × 104
cells per well and cultured with or without inhibitors, as
indicated. When control cells reached confluency, all
cells were fixed in 4% formaldehyde and stained with
0.1% crystal violet (in water).
Live cell growth was measured by automated deter-
mination of confluency every 4 h using IncuCyte Zoom
(Essen Bioscience). Between 600 and 800 cells were
plated per well of a 96-well plate, and experiments were
carried out in triplicates.
MEK inhibitors selumetinib (AZD6244) and trametinib
(GSK1120212) were purchased from Selleck Chemicals
and kept as 10mM stock solutions in DMSO. ERN1 in-
hibitor (compound 18) and JNK inhibitor SR-3306 were
kindly provided by Astex Pharmaceuticals. TAK1 inhibitor
was purchased from Merck as (5Z)-7-Oxozeaenol (CAS
66018-38-0).
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Protein lysate preparation and western blot analysis
Cells were lysed and western blots performed as de-
scribed previously [12]. Primary antibodies against
HSP90 (sc-13119), p-JUN (sc-822), and ERK2 (sc-154)
were purchased from Santa Cruz. Antibodies against
ERN1 (#3294), GAPDH (#5174), p-ERK1/2 (#9101), and
JUN (#9165) were from Cell Signaling. Antibodies
against COP1 (Genentech, 28A4) and DET1 (Genentech,
3G5) were a gift from Vishva Dixit, Genentech. Second-
ary antibodies were obtained from Bio-Rad Laboratories.
Total RNA isolation and quantitative RT-PCR
Total RNA was isolated and purified using Quick-RNA™
MiniPrep (Zymo Research), and reverse transcription
was performed with Maxima Universal First Strand
cDNA Synthesis Kit (Thermo Fisher Scientific, #K1661).
The 7500 Fast Real-Time PCR System from Applied
Biosystems was used to measure mRNA levels, which
were normalized to the expression of GAPDH, in tripli-
cates. The following primer sequences were used in the










JNK2-Rev, TCCAGCTCCATGTGAATAACCT. To detect
human XBP1 mRNA, we used hXBP1-Fw, GAAGCCAAG
GGGAATGAAGT and hXBP1-Rev, GCTGGCAGGCTC
TGGGGAAG. To detect human spliced Xbp1, hXBP1-Rev
was used with hXBP1spl-Fw, TGCTGAGTCCGCAGCAG
GTG, as designed previously [13].
CRISPR-Cas9 resistance screen
To generate ERN1 knockout cells that would not contain
the same tracer sequence as currently available CRISPR
libraries and thus be suitable for subsequent genome-
wide screening, we used a dual vector doxycycline-
inducible CRISPR/Cas9 system made on the basis of
FH1tUTG [14], as previously described [15]. Single-cell
clones were tested for ERN1 knockout by western blot
and by measuring the levels of spliced XBP1 using
quantitative RT-PCR as described above.
Version 2 of the human genome-scale CRISPR-Cas9
knockout (GeCKO) half-library A—consisting of 65,383
sgRNAs in lentiviral vectors [16] (Addgene #1000000048)—
was used to infect LoVo ERN1 knockout cells with a
transduction efficiency of 20% in a sufficient cell num-
ber to achieve a 180-fold library coverage. After 48 h,
cells were replated and viral supernatant was replaced
by medium containing puromycin (2 μg/ml) to select
for infected cells for 2 days. After additional 4 days of
growth, cells were harvested, a T0 sample was taken,
and the rest of the cells were reseeded and cultured in
the presence or absence of MEK inhibitors selumetinib
and trametinib, in two biological replicates each, for 4
weeks. Genome-integrated sgRNA sequences were PCR
amplified and their respective abundance was deter-
mined as described previously [17]. The abundance of
each sgRNA in the treated versus untreated pools was
determined by massively parallel sequencing on an Illu-
mina HiSeq 2500 platform. Statistical analysis was per-
formed using DESeq version 1.24.0. The hit selection
was based on the overlap between selumetinib and trame-
tinib screens for the genes for which at least one of the
sgRNAs meet the following criteria: (A) log2 fold change
(of treated over untreated samples) ≥ 7, (B) baseMeanA
(mean number of reads in the untreated sample) ≥ 50, and
(C) adjusted p value ≤ 0.1. The results overview of the
CRISPR screen can be found in Additional file 1: Tables
S5 and S6.
Results
RAS synthetic lethality screens in yeast
To discover genetic interactions with mutant yeast RAS,
we expressed the constitutively active RAS alleles,
RAS1(V19), and RAS2(V19), in the collection of ~ 4800
yeast strains in which each individual nonessential gene
is deleted [11]. To discriminate between effects due to
ectopic expression of the RAS alleles and those due to
the specific RAS gene mutations, we also screened the
wild-type RAS1(wt) and RAS2(wt) alleles. Additionally,
we screened cells harboring an empty vector as a con-
trol. Median-normalized growth values were used to cal-
culate the growth ratios between experimental and
vector control colonies (Additional file 2: Figure S1A)
[18]. We have shown previously that a screen organizes
related genes based on phenotype, and these genes ex-
hibit a high density of interactions within the group. The
CLIK algorithm plots this density of interactions from
the ranked screen results to determine a cutoff for the
screen [19]. CLIK analysis of the RAS1(V19) and
RAS2(V19) screens yielded respectively 151 and 450
strains with a growth defect, which corresponds to a
twofold difference in growth compared to the population
median in both screens (Additional file 1: Table S1). Al-
though no CLIK groups were identified for the RAS1(wt)
and RAS2(wt) screens, the same twofold growth differ-
ence cutoff was applied, which yields 14 affected strains
from each screen (Additional file 2: Figure S1B-E) indi-
cating that the majority of SL interactions are specific to
the activated RAS mutants. Interestingly, most SLs from
the RAS1(V19) were also found in the RAS2(V19) screen
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(Additional file 2: Figure S1F). The growth effects in the
RAS1(V19) and RAS2(V19) screens were highly corre-
lated although the effect was more severe in the
RAS2(V19) screen (Additional file 2: Figure S1G). This
finding suggests that the yeast RAS genes form a quanti-
tative redundant pair [20].
To validate the deletion mutants from the SL screens,
the strains that showed an SL interaction were rescreened
with a mutant or wild-type RAS allele. Forty-six percent of
the RAS1(V19) and 79% of the RAS2(V19) SLs from the
primary screen also had a growth defect (> 2 times smaller
than control) in the validation screen (Additional file 1:
Tables S2-S5). Ninety percent of the validated hits of the
RAS1(V19) screen overlapped with the RAS2(V19) screen.
The gene deletions from the RAS1(wt) and RAS2(wt)
screens did not validate in a second screen, indicating that
the SLs are specific to the mutant alleles and that
RAS1(V19) interacts with a subset of the RAS2(V19) SLs
(Fig. 1a). We decided to focus on the genes from the
RAS2 mutant screen due to the higher number of interac-
tions and the higher validation rate. In addition, almost all
of the RAS1 mutant gene deletions were also found and
validated in the RAS2 screen.
An encouraging sign of the validity of our screen was
the recapitulation of the synthetic lethal interaction be-
tween RAS2(V19) and SIN4. SIN4 is a component of the
mediator transcription complex (MED16), and its inter-
action with RAS2(V19) has been described before [21].
Additionally, we found that another mediator compo-
nent, PGD1 (MED3), is synthetic lethal with RAS2(V19).
We performed a Gene Ontology (GO) enrichment
analysis on the SLs from the RAS2(V19) screen, which
identified a variety of biological processes enriched in
this screen, including endosomal transport and protein
targeting (Fig. 1b). This finding indicates that cells ex-
pressing RAS2(V19) are highly dependent on intracellu-
lar protein transport. We further analyzed the validated
list of RAS2(V19) SLs by identifying protein complexes
from which two or more members were present, based
on Benschop et al [22]. Again, in this analysis, we recov-
ered several complexes involved in endosomal transport
(Fig. 1c). Based on the dependence of cells expressing
RAS2(V19) on intracellular transport, we hypothesized
that ER homeostasis was disturbed in these cells, which
would be consistent with the work of Leber et al [23].
To test this hypothesis, we compared our list of
RAS2(V19) SLs to lists of strains that are sensitive to ER
stress agents [24]. We confirmed a significant overlap
with strains sensitive to β-mercaptoethanol, DTT,
and tunicamycin (P = 3.07E−05, hypergeometric test;
Additional file 1: Table S6), suggesting that ER homeosta-
sis is disturbed by RAS2(V19).
Mutant RAS is known to inhibit the production of
GPI-anchors at the ER [25]. This inhibition likely
contributes to permanent ER stress in cells expressing
RAS2(V19). To test this theory, we compared the effect of
expressing RAS2(V19) with directly inhibiting GPI-anchor
production by analyzing the synthetic lethal genetic interac-
tions of ERI1, a non-essential component of the GPI-GnT
enzyme [26]. Again, we found a significant overlap between
the RAS2(V19) SLs lists and the list of ERI1 genetic interac-
tions (P = 8.60E−09, hypergeometric test; Additional file 1:
Table S7). The strongest negative genetic interaction of
ERI1 is with IRE1, an important regulator of the UPR. Add-
itionally, ERI1 shows a strong negative genetic interaction
with HAC1, a downstream target of Ire1. The UPR is a
signaling route that restores ER homeostasis and ire1Δ
and hac1Δ strains are highly sensitive to ER stress agents
(Additional file 1: Table S6). Importantly, we found both
IRE1 and HAC1 are RAS2(V19) SLs (Fig. 1d, e), indicating
that ER homeostasis is disturbed in RAS2(V19) expressing
cells and that these cells are dependent on the UPR.
Genetic ablation of ERN1 in KRAS mutant colon cancer
cells
The UPR, and the mechanism of activation by splicing of
a specific mRNA, is conserved from yeast to humans
(Fig. 1f). Mammalian cells have an IRE1 ortholog, named
ERN1, while HAC1 has a functional human homolog
named XBP1, whose mRNA is spliced by the ERN1 endo-
nuclease domain to form the active, protein-coding XBP1
spliced (XBP1s) form [9]. To test whether ERN1 is essen-
tial in cells with active RAS signaling, we created ERN1
knockout (KO) LoVo, HCT-116, SW480, and DLD1
KRAS mutant colon cancer cells using lentiviral CRISPR-
Cas9 vectors. ERN1 KO cells had an absence of ERN1
protein and a strong decrease in spliced XBP1 (XBP1s)
(Fig. 2a–d). We found that the proliferation of ERN1KO
cells was similar to control cells expressing non-
targeting (NT) gRNA, indicating that the synthetic le-
thal interaction between RAS and the UPR is not
conserved between yeast and human cells. However,
since yeast cells are missing the RAF/MEK/ERK MAPK
cascade, we investigated the proliferation of the KRAS
mutant ERN1KO cells in the presence of the MEK in-
hibitor selumetinib (AZD6244). Interestingly, we found
increased MEK inhibitor sensitivity in all ERN1KO
LoVo, HCT-116, and SW480 cell clones, both in
short-term and in long-term assays (Fig. 2e–g and
Additional file 2: Figure S2A-C). In DLD1 cells, no ef-
fect on selumetinib response was observed upon ERN1
KO (Additional file 2: Figure S2D-F). These data indi-
cate that a subset of KRAS mutant colon cancer cells
can be sensitized to MEK inhibition by loss of ERN1.
Pharmacologic inhibition of ERN1
The ERN1 protein contains both an endonuclease and a
kinase domain. A specific inhibitor of ERN1 kinase activity
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has been developed that results in allosteric inhibition of
the endonuclease activity, referred to as compound 18 by
Harrington et al [27]. We tested the potency of this inhibi-
tor in LoVo cells by measuring XBP1s levels 24 h after
treatment with increasing amounts of ERN1 inhibitor.
The compound proved effective with an IC50 of approxi-
mately 100 nM (Fig. 2h). Next, we tested whether treat-





Fig. 1 Unfolded protein response (UPR) executors are synthetic lethal with mutant RAS in S. cerevisiae. a Venn diagram showing the overlap of
the RAS synthetic lethal (SL) gene deletion strains identified in the RAS1(V19) and RAS2(V19) genetic screens. b Gene Ontology (GO) enrichment
analysis on the SL gene deletion strains from the RAS2(V19) screen identifies a variety of biological processes, including endosomal transport and
protein targeting. c List of genes coding for protein complexes among the validated list of RAS2(V19) SL gene deletion mutants. Higher values
correspond to stronger growth arrest in the presence of mutant RAS. The pathways and complexes in which the genes are involved are indicated. d The
effect of the deletion of the UPR stress sensor IRE1 (ire1Δ) in RAS2(V19) screen (top) and in the empty vector (EV) control background (bottom). e Control
vs mutant growth ratios of the UPR genes IRE1 and HAC1. Higher values correspond to stronger growth arrest in the presence of mutant RAS. f Schematic
representation of the evolutionary conserved mechanism of UPR execution in yeast (top) and humans (bottom). Ire1 is responsible for the editing of HAC1
mRNA which produces an active executor of the UPR. ERN1 is the human ortholog of yeast IRE1; XBP1 is a functional human homolog of HAC1
Šuštić et al. Genome Medicine           (2018) 10:90 Page 5 of 13
sensitivity of LoVo cells to the MEK inhibitor. To our sur-
prise, inhibition of ERN1 endonuclease activity was not
sufficient to recapitulate the phenotype of the genetic ab-
lation of ERN1 (Fig. 2i).
ERN1 is able to cleave other mRNAs besides XBP1, a
process termed regulated IRE1-dependent decay (RIDD)
[28]. We tested whether the ERN1 inhibitor interfered
with RIDD by stressing LoVo cells with the ER
A B C D
E F
G
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Fig. 2 Effects of ERN1 inhibition in KRAS mutant human colon cancers. a, b Western blot analysis of ERN1 expression in control cells expressing
non-targeting (NT) gRNA and LoVo ERN1KO clones 5B, 6B, and 7B (a) and HCT-116 ERN1KO clones C1, C2, and C3 (b). c, d qPCR analysis of spliced
XBP1 mRNA (XBP1s) in control cells expressing non-targeting (NT) gRNA and LoVo ERN1KO clones 5B, 6B, and 7B (c) and HCT-116 ERN1KO clones
C1, C2, and C3 (d). Error bars indicate standard deviation calculated from three biological replicates. e Representative colony formation assays of
three different ERN1KO clones compared to the non-targeting (NT) gRNA expressing control cells in the KRAS mutant LoVo (top) and HCT-116
colon cancer cells (bottom). Cells were maintained in the indicated range of concentrations of the MEK inhibitor selumetinib (AZD6244) for 10
days, stained and photographed. f, g Live cell proliferation assay (IncuCyte®) of control (NT gRNA) and ERN1KO cells following exposure to the
MEK inhibitor AZD6244. Error bars indicate standard deviation of three replicate experiments. h qPCR analysis of spliced XBP1 mRNA (XBP1s)
levels following exposure of LoVo cells to increasing concentrations of the ERN1 kinase inhibitor. Error bars indicate standard deviation calculated
from three replicate experiments. i Colony formation assay showing the effect of ERN1 kinase inhibitor on the proliferation of KRAS mutant
LoVo cells in the presence of the indicated concentrations of the MEK inhibitor AZD6244. j Quantification of spliced XBP1 mRNA (XBP1s) levels
following 1 h treatment with 100 nM of ER stress inducer thapsigargin (Tg) in the presence and absence of the ERN1 kinase inhibitor. k
Quantification of the mRNA levels of the RIDD target CD59 after 1 h treatment with 100 nM thapsigargin (Tg) in the presence and absence of
the ERN1 kinase inhibitor
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stress-inducing agent thapsigargin (Tg) both in the ab-
sence and presence of the ERN1 kinase inhibitor. One of
the RIDD targets is CD59 [29]. As expected, XBP1 levels
increased and CD59 mRNA levels decreased upon treat-
ment with Tg. In the presence of the ERN1 inhibitor,
XBP1 splicing was not increased and CD59 mRNA levels
did not decrease upon treatment with Tg (Fig. 2j, k).
These data show that RIDD is effectively inhibited by
the ERN1 inhibitor and that RIDD targets are unlikely to
be involved in the sensitization of ERN1KO cells to the
MEK inhibitor.
Genome-wide screen reveals ERN1-JNK-JUN signaling axis
To identify a mechanistic link between the ERN1 and
the RAF/MEK/ERK signaling pathway, we performed a
genome-scale CRISPR/Cas9 MEK inhibitor resistance
screen using ERN1KO LoVo cells. We screened in the
presence and absence of two different MEK inhibitors,
selumetinib and trametinib (Fig. 3a) and used differential
analysis to identify the genes whose knockout confers re-
sistance to MEK inhibitors. Considering that the CRISPR
library used contained only three sgRNAs per gene tar-
get, we decided not to impose the criterion of multiple
sgRNAs per gene. Nevertheless, we found that four hits
(DET1, DUSP4, RUNX2 and STK40) were represented
by multiple different sgRNAs, while two hits (COP1
and CBFB) each scored with a single sgRNA both in
selumetinib and in trametinib screen (Fig. 3b and c).
A complete list of screen results can be found in
Additional file 1: Tables S8 and S9.
Dual specificity phosphatase-4 (DUSP4) has been pre-
viously implicated in regulating the response to MEK in-
hibitors, validating the screen performed here [30, 31].
Serine/threonine kinase 40 (STK40) is a negative regula-
tor of NF-κB [32, 33], and NF-κB activity was already
shown to directly modulate resistance to several differ-
ent MAPK pathway inhibitors [34]. In contrast, the
remaining four genes (DET1, COP1, CBFB, and RUNX2)
have not previously been implicated in MAPK signaling
or MEK inhibitor resistance. Interestingly, these four
genes code for proteins that act pair-wise in complex
with each other. The functional and physical interaction
between RUNX2 (also known as core-binding factor
subunit alpha-1 or CBFA1), and its transcriptional co-
activator CBFB (core-binding factor subunit beta) has
been well documented using various in vitro [35] and in
vivo model systems [36–39]. DET1 and COP1 are part
of an E3 ubiquitin ligase complex that promotes ubiqui-
tination and degradation of the proto-oncogenic tran-
scription factor JUN [40]. Because of a previously
established link between ERN1 and JNK [41], we studied
DET1 and COP1 further to understand the effects of
ERN1 loss on the response to MEK inhibitors.
DET1 and COP1 are regulators of MEK inhibitor response
To validate the results of the genetic screen, we knocked
out DET1 and COP1 in ERN1-deficient LoVo cells. Import-
antly, both in long-term assays (Fig. 3d, and Additional file 2:
Figure S3) and in short-term assays (Fig. 3e) loss of either
DET1 or COP1 conferred resistance to selumetinib and tra-
metinib in these cells. Both vectors were effective in knock-
ing out their respective targets in a polyclonal knockout cell
population (Fig. 3f). In addition, biochemical analysis re-
vealed higher basal JUN levels in DET1- and COP1-
negative cell populations, consistent with the fact that
DET1 and COP1 are part of an E3 ubiquitin ligase complex
that degrades JUN [40]. Moreover, computational analyses
of drug response data in a large cancer cell line panel [42]
further supports that high DET1 or COP1 expression is
correlated with low IC50 values (i.e., sensitivity) for five dif-
ferent MEK inhibitors across a colorectal cancer cell line
panel (Fig. 3g).
Besides an endonuclease and a kinase function, human
ERN1 regulates JNK signaling through binding of the
adaptor protein TRAF2 [41], which activates JNK to
phosphorylate the transcription factor JUN. We tested if
active JNK signaling is important for MEK inhibitor sen-
sitivity by directly knocking down JUN using shRNAs.
We found that LoVo cells are dependent on JUN for
proliferation upon treatment with MEK inhibitor. Im-
portantly, the sensitivity of the LoVo cells to treatment
with MEK inhibitor correlated with the levels of JUN
protein (Fig. 4a). To investigate if ERN1 is required for
the activation of JUN, we compared JUN phosphoryl-
ation in ERN1KO cells to control cells, in the presence
and absence of MEK inhibitor. We observed a strong in-
crease in JUN phosphorylation in ERN1 WT cells, com-
pared to ERN1KO cells, after 4 h of MEK inhibitor
treatment (Fig. 4b). Consistently, we found that JUN
expression is increased by MEK inhibitor in parental
cells, but not in ERN1KO cells, which is not caused by
expression changes of either JNK1 or JNK2 mRNA
(Additional file 2: Figure S4 and S5). These results indi-
cate that ERN1-deficient cells are unable to fully acti-
vate JUN signaling, which may explain the MEK
inhibitor sensitivity of ERN1KO cells. Moreover, we
found that MEK inhibitor treatment induces ERN1 ac-
tivity, an effect not seen in ERN1KO cells (Fig. 4c).
Finally, we tested if directly inhibiting JNK kinase sig-
naling with a JNK kinase inhibitor would sensitize LoVo
cells to MEK inhibition. The potency and specificity of
the JNK inhibitor SR-3306 was tested by measuring
phosphorylated JUN levels upon treatment of cells with
the ER stress-inducing agent thapsigargin (Tg) (Fig. 4d).
We found that LoVo cells were sensitive to the combin-
ation of JNK and MEK inhibition (Fig. 4e, f ). This effect
was also found by blocking TAK1, a kinase upstream of
JNK (Fig. 4g–i).






Fig. 3 (See legend on next page.)
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Discussion
Although the yeast and human RAS genes have many
properties that are interchangeable, the signaling path-
ways that are controlled by them differ. Here, we find
that both yeast and human RAS share a link with the
UPR. The shared interaction suggests that an analogous
genetic network structure evolved connecting both yeast
and human RAS to the ER stress signaling. Using
genome-wide synthetic lethality screens in yeast, we
identified multiple genes necessary for ER homeostasis,
including the UPR stress sensor IRE1, to be SL with mu-
tant RAS. This genetic interaction was not observed in
KRAS mutant colon cancer cells, which are unaffected
by genetic ablation of ERN1, the human ortholog of
IRE1. However, in contrast to yeast, human cells possess
a RAF/MEK/ERK MAPK pathway, and inhibiting this
pathway uncovers the SL interaction between ERN1KO
and mutant KRAS. Although we conclude that ERN1 it-
self is dispensable for cell growth and proliferation, we
find that its loss can sensitize KRAS mutant colon can-
cer cells to MEK inhibition. Considering unsatisfactory
performance of MEK inhibitors in clinical trials [43–45],
we used ERN1 knockout colon cancer cells as a model
to study resistance mechanisms to MEK inhibition. As
small molecule ERN1 inhibitors failed to enhance sen-
sitivity to MEK inhibition, we resorted to genetic
screens to explore the mechanism responsible for the
observed synthetic lethality effect. Our genome-wide
CRISPR/Cas9 screen identified a series of genetic
events that can reinstate MEK inhibitor resistance in
ERN1 knockout colon cancer cells. One of the most
prominent hits in this screen was dual specificity
phosphatase-4 (DUSP4), a well-established tumor sup-
pressor that negatively regulates JUN N-terminal kin-
ase JNK. Upon loss of DUSP4, derepressed JNK activity
stimulates JUN-mediated transcription, leading to ab-
errant MAPK pathway activation [31]. Interestingly,
two other screen hits, DET1 and COP1, are also nega-
tive regulators of JUN.
Originally described as regulators of light signaling in
Arabidopsis thaliana [46], both DET1 (de-etiolated
homolog 1) and COP1 (constitutive photomorphogenic
1, also known as RFWD2) mechanistically function as
E3 ubiquitin-protein ligases and are evolutionarily con-
served members of the COP-DET-FUS protein family.
Extensive biochemical studies have shown that COP1-
DET1 complex targets JUN for ubiquitination and deg-
radation [40]. Further characterization of in vivo models
established the role of human COP1 as a tumor suppres-
sor [47–49]. Here we uncover a role for human COP1
and DET1 in resistance to MEK inhibitors via inhibition
of the JNK-JUN pathway.
Since three of the genes identified in our resistance
screen (DUSP4, DET1, and COP1) are negative regula-
tors of JUN, we propose that activated ERN1 leads to in-
creased JUN activity, which then translates to cell
proliferation despite the inhibition of MEK. ERN1 is
linked to the JUN pathway via its binding factor TRAF2,
which executes a signaling cascade resulting in the acti-
vation of JUN N-terminal kinase JNK [41]. Furthermore,
our work demonstrates that the kinase and endonuclease
domains of ERN1 are not responsible for the differential
sensitivity to MEK inhibition. Recently, we showed that
cancers that fail to activate JNK-JUN, due to inactivating
mutations in upstream kinases MAP3K1 and MAP2K4,
are sensitive to MEK inhibition [50]. Here we demon-
strate that ERN1KO cells also fail to activate the JNK-
JUN pathway resulting in a similar sensitivity to MEK
inhibition.
We propose that the JNK arm of MAPK signaling can
functionally compensate for the inhibition of the MEK/
ERK signaling axis. Conversely, under conditions of ab-
rogated JNK signaling, such as in the presence of JNK or
TAK1 inhibitors, cells become more dependent on the
flux of signal through the MEK/ERK pathway. This de-
pendency could then prove to be of therapeutic import-
ance. We speculate that cells in which ERN1 knockout
does not sensitize to MEK inhibition (such as DLD1
(See figure on previous page.)
Fig. 3 A genetic screen for resistance to MEK inhibitors in ERN1 knockout colon cancer. a Schematic outline of the genome-scale CRISPR/Cas9
knockout screen for resistance to MEK inhibition. Two different MEK inhibitors, selumetinib and trametinib, were used, each in two replicates, and
compared to the untreated control population. b, c MA plots of the selumetinib (b) and trametinib screens (c). Horizontal dashed line indicates
an arbitrarily imposed threshold of log2 (fold change of treated over untreated) of 7 and vertical dashed line indicates mean number of reads in
untreated samples of 50. Highlighted in color are the sgRNAs targeting DUSP4, DET1, COP1, CBFB, RUNX2, and STK40, that are found above these
two thresholds (with the p adjusted of ≤ 0.1) in both the selumetinib (b) and the trametinib (c) screen. d, e Functional validation of DET1 and
COP1 in LoVo ERN1KO background. d Colony formation assays of DET1 and COP1 KO cells in the presence and absence of the MEK inhibitor
AZD6244 (selumetinib) are shown relative to control cells having NT gRNA. Shown is a representative example of at least three biological
replicates. e Live cell proliferation assay of DET1 and COP1 KO cells in the presence and absence of 1 μM AZD6244 compared to control cells
expressing NT gRNA. Error bars indicate standard deviation calculated from three replicate experiments. f Western blot analysis of DET1 and COP1
expression in DET1 and COP1 knockout cells using antibodies against ERN1, DET1, COP1, JUN, p-ERK, and HSP90 as control both in the presence
and absence of the MEK inhibitor AZD6244. g Median-centered log(IC50) of five different MEK1 inhibitors in high (top 25%) and low (bottom
25%) expressing DET1 (left) and COP1 (right) CRC cell lines in the GDSC100 data set [42]. Cell lines with high DET1 or COP1 expression have
significantly lower IC50s (p = 0.004 for both DET1 and COP1). Log(IC50) estimates were median-centered over all cell lines to make them
comparable between MEK inhibitors







Fig. 4 (See legend on next page.)
Šuštić et al. Genome Medicine           (2018) 10:90 Page 10 of 13
cells, Additional file 2: Figure S2A-C) can activate JNK-
JUN signaling through other pathways, thereby making
such cells independent of ERN1 for their MEK inhibitor
response. Alternatively, other pathways may be involved
in MEK inhibitor resistance in these cells.
We report synergistic cell growth arrest when JNK
and MEK inhibitors are combined. Moreover, inhibition
of JNK itself (Fig. 4d, e) or JNK activators, such as TAK1
(Fig. 4g, h), might also be useful in preventing intrinsic
resistance to MEK inhibitors. In this study, we made use
of the resorcyclic lactone (5Z)-7-oxozeanol (5ZO) as a
TAK1 inhibitor. However, considerable off-target effects
render this molecule inadequate for therapeutic pur-
poses. It remains to be seen whether recently developed
TAK1 inhibitors [51] give a more favorable toxicologic
profile in the clinic. Taken together, our findings identify
an unexpected role for the Unfolded Protein Response
executor ERN1 in determining the response to MEK in-
hibition in KRAS-driven colon cancer.
Conclusions
We identify here a set of genes involved in endosomal
transport and ER stress that are synthetic lethal with
mutant RAS in yeast. At the crossroads of these pro-
cesses, we identify IRE1 and HAC1 that are not only syn-
thetic lethal with hyperactivated RAS signaling in yeast,
but also with ERI1, a non-essential component of the
GPI-GnT enzyme which mediates ER stress response.
The fact that IRE1 and HAC1 are both master regulators
of the unfolded protein response (UPR) indicates that
ER homeostasis is disturbed in mutant RAS expressing
cells and that these cells are dependent on the UPR.
Moreover, in human colon cancer cell lines, we find
that MAPK pathway shields KRAS mutant cells from
synthetic lethality with ERN1, a human ortholog of IRE1.
These interactions point to an evolutionarily conserved
genetic network structure between RAS signaling and
ER stress.
Finally, we find that ERN1 is an important regulator of
JUN activity, which becomes crucial for survival in
KRAS mutant colon cancer under conditions of abro-
gated MAPK signaling. We identify the ERN1-JNK-JUN
pathway as a novel regulator of MEK inhibitor response
in KRAS mutant colon cancer, and point to synthetic le-
thality of MEK inhibition with therapeutics targeting
JUN activating kinases, TAK1 and JNK. The genetic net-
work connecting JUN and MAPK signaling may explain
why KRAS mutant tumor cells are traditionally seen as
highly refractory to MEK inhibitor therapy, but these
genetic interactions may also provide a therapeutically
exploitable vulnerability.
Additional files
Additional file 1: contains Tables S1-S9. Table S1. Results of the
primary yeast screen with RAS alleles RAS1 and RAS2 (wild-type) and
mutants RAS1(V19) and RAS2(V19). Table S2. Results of the validation
yeast screen for RAS1. Table S3. Results of the validation yeast screen for
RAS2. Table S4. Results of the validation yeast screen for RAS1(V19).
Table S5. Results of the validation yeast screen for RAS2(V19). Table S6.
Gene deletion yeast strains sensitive to ER stress agents (Y. Chen et al.,
Mol Cancer Res 2005 [23]) and strains sensitive to the expression of
RAS2(V19). Table S7. Gene deletion yeast strains sensitive to ERI1
deletion (M. Costanzo et al., Science 2010 [25]) and strains sensitive
to the expression of RAS2(V19). Table S8. Results of the genome-
wide CRISPR/Cas9 screen with the MEK inhibitor AZD6244 (selumetinib).
Table S9. Results of the genome-wide CRISPR/Cas9 screen with the MEK
inhibitor trametinib. (XLSX 15504 kb)
Additional file 2: Figure S1. Genome-wide synthetic lethal screens with
RAS1(V19) and RAS2(V19) identify overlapping sets of genes. Figure S2.
The response of SW480 ERN1KO and DLD1 ERN1KO KRAS mutant colon
cancer cells to MEK inhibition. Figure S3. Colony formation assays of
DET1 and COP1 knockout cells (in LoVo ERN1KO background) in the
presence and absence of the MEK inhibitor trametinib are shown relative
to control cells expressing non-targeting (NT) gRNA. Figure S4.
Quantification of JUN expression levels in MEK inhibitor (MEKi, 1 μM
(See figure on previous page.)
Fig. 4 Effect of genetic and pharmacologic downregulation of JUN on response to MEK inhibition. a Five different JUN targeting shRNAs were
used to downregulate JUN in LoVo cells. JUN protein levels were quantified by western blotting (top), and the response to increasing concentrations
of the MEK inhibitor AZD6244 on JUN knockdown cells is shown in colony formation assay (bottom). Empty vector infected control (ctrl) cells are
shown here for comparison. b Biochemical analysis comparing ERN1KO cells with their control counterparts (ctrl) in the presence and absence of the
MEK inhibitor AZD6244 for the indicated number of hours. One-hour thapsigargin treatment (Tg) at 0.1 μM was used as a control for p-JUN induction.
c Quantification of spliced XBP1 mRNA (XBP1s) in the presence and absence of 1 μM AZD6244 at indicated time points. Error bars indicate standard
deviation calculated from three replicate experiments. d Biochemical analysis of JUN phosphorylation in the presence and absence of increasing
concentrations of the JNK inhibitor SR-3306. One-hour of thapsigargin treatment (Tg) at 0.1 μM was used for p-JUN induction. e A representative
colony formation assay of LoVo cells grown in the increasing concentrations of the JNK inhibitor SR-3306 (horizontally) and the increasing
concentrations of the MEK inhibitor AZD6244 (vertically). f Live cell proliferation assay for the combination of the MEK inhibitor AZD6244 and
the JNK inhibitor SR-3306 (black), each inhibitor individually (red and blue), and vehicle-treated control cells (yellow line). Error bars indicate
standard deviation calculated from three replicate experiments. g Schematic representation of the signaling from the endoplasmic reticulum
(ER) embedded ERN1 to JNK and JUN via its binding factor TRAF2 and TAK1. Shown in yellow are resistance screen hits DUSP4, DET1, and
COP1, which are all negative regulators of JNK and JUN, respectively. h A representative colony formation assay showing the effect of the
TAK1 inhibitor (5Z)-7-oxozeanol (5ZO) on the proliferation of KRAS mutant LoVo cells in the presence of the indicated concentrations of the
MEK inhibitor AZD6244. i Live cell proliferation assay for the combination of the MEK inhibitor AZD6244 and TAK1 inhibitor 5ZO over the
course of 10 days (240 h). Yellow line shows vehicle-treated control cells. Error bars indicate standard deviation calculated from three
replicate experiments
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AZD6244), JNK inhibitor (JNKi, 1 μM SR-3306) and combination treatment
(JNKi + MEKi). One-hour thapsigargin treatment (Tg, 100 nM) was used as a
control. Error bars represent standard deviation of three replicate
experiments. Figure S5. Quantification of JNK1 (A) and JNK2 (B)
expression levels in MEK inhibitor (MEKi, 1 μM AZD6244), JNK inhibitor
(JNKi, 1 μM SR-3306) and combination treatment (JNKi + MEKi). One-
hour thapsigargin treatment (Tg, 100 nM) was used as a control. Error bars
represent standard deviation of three replicate experiments. (PDF 11800 kb)
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